AHF confronts PhRMA ahead of 340B hearing
With medicine affordability in the USA again becoming headline news on Monday due to President Trump’s tweeting on Pfizer’s (NYSE: PFE) pricing, another big day for pharma and patients is potentially in store on Wednesday.
The US House of Representatives’ Energy & Commerce Subcommittee on Health will hold a hearing on the 340B drug pricing program amid pressure from different players in the healthcare debate.
Pharmaceuticals Research Manufacturers of America (PhRMA), the trade group that represents the pharmaceutical industry in the USA, is calling on Congress to ‘fix 340B’ and has run adverts on the Politico Pro site saying that ‘virtually every stakeholder has raised concerns’ with the program.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze